Privium Fund Management B.V. Acquires 89,000 Shares of Urogen Pharma $URGN

Privium Fund Management B.V. boosted its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 82.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 196,622 shares of the company’s stock after buying an additional 89,000 shares during the quarter. Urogen Pharma accounts for approximately 0.7% of Privium Fund Management B.V.’s portfolio, making the stock its 23rd biggest holding. Privium Fund Management B.V.’s holdings in Urogen Pharma were worth $3,923,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its stake in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares during the last quarter. Strs Ohio purchased a new stake in shares of Urogen Pharma in the 3rd quarter worth $76,000. CWM LLC raised its holdings in Urogen Pharma by 18.0% in the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after purchasing an additional 650 shares during the period. Tower Research Capital LLC TRC lifted its position in Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Urogen Pharma by 9.4% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock valued at $127,000 after purchasing an additional 797 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Urogen Pharma in a research note on Monday, October 27th. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a report on Friday, January 23rd. Finally, Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Urogen Pharma Price Performance

Urogen Pharma stock opened at $19.61 on Friday. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00. The firm’s 50 day moving average price is $22.76 and its 200-day moving average price is $20.45. The stock has a market cap of $917.94 million, a P/E ratio of -5.67 and a beta of 1.29.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.03. The company had revenue of $27.48 million for the quarter, compared to analysts’ expectations of $34.09 million. As a group, equities analysts expect that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the insider owned 139,025 shares in the company, valued at $3,475,625. This trade represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.70% of the company’s stock.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.